

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



88/10

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) -

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12Q 1/68</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 99/28500</b> <b>(43) International Publication Date:</b> 10 June 1999 (10.06.99)
<b>(21) International Application Number:</b> PCT/GB98/03560 <b>(22) International Filing Date:</b> 27 November 1998 (27.11.98) <b>(30) Priority Data:</b> 9725197.9 29 November 1997 (29.11.97) GB <b>(71) Applicants (for all designated States except US):</b> THE SECRETARY OF STATE FOR DEFENCE [GB/GB]; Defence Evaluation and Research Agency, Ively Road, Farnborough, Hampshire GU14 0LX (GB). BIO/GENE LIMITED [GB/GB]; Bio/gene House, 6 The Business Centre, Harvard Way, Kimbolton, Cambs PE18 0NJ (GB). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> LEE, Martin, Alan [GB/GB]; CBD, Porton Down, Salisbury, Wiltshire SP4 0JG (GB). FUERST, Roderick [GB/GB]; Bio/gene Limited, Bio/gene House, 6 The Business Centre, Harvard Way, Kimbolton, Cambs PE18 0NJ (GB). <b>(74) Agent:</b> BOWDERY, Anthony, Oliver; D/IPR Formalities Section (Dera), Poplar 2, MOD Abbey Wood #19, Bristol BS34 8JH (GB).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> FLUORIMETRIC DETECTION SYSTEM OF A NUCLEIC ACID  <b>(57) Abstract</b>  A method for detecting the presence of a target nucleic acid sequence in a sample, said method comprising: (a) adding to a sample suspected of containing said target nucleic acid sequence, a probe specific for said target sequence and DNA duplex binding agent, said probe comprising a reactive molecule able to absorb fluorescence from or donate fluorescent energy to said DNA duplex binding agent, (b) subjecting the thus formed mixture to an amplification reaction in which target nucleic acid is amplified, (c) subjecting said sample to conditions under which the said probe hybridises to the target sequence, and (d) monitoring fluorescence from said sample. This method can be used for example to monitor amplification reactions such as PCR reactions, such that the amount of target sequence present in the sample may be determined. Additionally or alternatively, it may be used to generate duplex destabilisation data such as melt hysteresis information for amplification monitoring or for detection and quantitation of polymorphisms or allelic variation, and so is useful in genetic diagnosis.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## FLUORIMETRIC DETECTION SYSTEM OF A NUCLEIC ACID

The present invention provides a method for detecting a target polynucleotide in a sample, for example by  
5 quantitatively monitoring an amplification reaction, as well as to probes and kits for use in these methods. The method is particularly suitable for the detection of polymorphisms or allelic variation and so may be used in diagnostic methods

10

Known fluorescence polymerase chain reaction (PCR) monitoring techniques include both strand specific and generic DNA intercalator techniques that can be used on a few second-generation PCR thermal cycling devices.

15

Generic methods utilise DNA intercalating dyes that exhibit increased fluorescence when bound to double stranded DNA species. Fluorescence increase due to a rise in the bulk concentration of DNA during amplifications can be used to  
20 measure reaction progress and to determine the target molecule copy number. Furthermore, by monitoring fluorescence with a controlled change of temperature, DNA melting curves can be generated, for example, at the end of PCR thermal cycling.

25

When generic DNA methods are used to monitor the rise in bulk concentration of nucleic acids, these processes can be monitored with a minimal time penalty (compared to some other known assays discussed below). A single fluorescent  
30 reading can be taken at the same point in every reaction. End point melting curve analysis can be used to discriminate artefacts from amplicon, and to discriminate amplicons. Melting peaks of products can be determined for concentrations that cannot be visualised by agarose gel  
35 electrophoresis.

In order to obtain high resolution melting data, for example for multiple samples, the melt experiment must be performed

slowly on existing hardware taking up to five minutes. However, by continually monitoring fluorescence amplification, a 3D image of the hysteresis of melting and hybridisation can be produced. This 3D image is amplicon  
5 dependent and may provide enough information for product discrimination.

It has been found that DNA melting curve analysis in general is a powerful tool in optimising PCR thermal cycling. By  
10 determining the melting temperatures of the amplicons, it is possible to lower the denaturing temperatures in later PCR cycles to this temperature. Optimisation for amplification from first generation reaction products rather than the target DNA, reduces artefact formation occurring in later  
15 cycles. Melting temperatures of primer oligonucleotides and their complements can be used to determine their annealing temperatures, reducing the need for empirical optimisation.

20 The generic intercalator methods however are only quasi-strand-specific and therefore is not very useful where strand specific detection is required.

Strand specific methods utilise additional nucleic acid  
25 reaction components to monitor the progress of amplification reactions. These methods often use fluorescence energy transfer (FET) as the basis of detection. One or more nucleic acid probes are labelled with fluorescent molecules, one of which is able to act as an energy donor and the other  
30 of which is an energy acceptor molecule. These are sometimes known as a reporter molecule and a quencher molecule respectively. The donor molecule is excited with a specific wavelength of light which falls within its excitation spectrum and subsequently it will emit light  
35 within its fluorescence emission wavelength. The acceptor molecule is also excited at this wavelength by accepting energy from the donor molecule by a variety of distance-dependent energy transfer mechanisms. A specific example of

fluorescence energy transfer which can occur is Fluorescence Resonance Energy Transfer or "FRET". Generally, the acceptor molecule accepts the emission energy of the donor molecule when they are in close proximity (e.g. on the same, or a neighbouring molecule). The basis of fluorescence energy transfer detection is to monitor the changes at donor and acceptor emission wavelengths.

There are two commonly used types of FET or FRET probes, those using hydrolysis of nucleic acid probes to separate donor from acceptor, and those using hybridisation to alter the spatial relationship of donor and acceptor molecules.

Hydrolysis probes are commercially available as TaqMan™ probes. These consist of DNA oligonucleotides that are labelled with donor and acceptor molecules. The probes are designed to bind to a specific region on one strand of a PCR product. Following annealing of the PCR primer to this strand, Taq enzyme extends the DNA with 5' to 3' polymerase activity. Taq enzyme also exhibits 5' to 3' exonuclease activity. TaqMan™ probes are protected at the 3' end by phosphorylation to prevent them from priming Taq extension. If the TaqMan™ probe is hybridised to the product strand, an extending Taq molecule may also hydrolyse the probe, liberating the donor from acceptor as the basis of detection. The signal in this instance is cumulative, the concentration of free donor and acceptor molecules increasing with each cycle of the amplification reaction.

The fact that signal generation is dependent upon the occurrence of probe hydrolysis reactions means that there is a time penalty associated with this method. Furthermore, the presence of the probe may interrupt the smooth operation of the PCR process.

In addition, it has been found that hydrolysis can become non-specific, particularly where large numbers of amplification cycles, for instance more than 50 cycles, are

required. In these cases, non-specific hydrolysis of the probe will result in an unduly elevated signal.

This means that such techniques are not very compatible with  
5 rapid PCR methods which are becoming more prominent with the development of rapid hot air thermal cyclers such as the RapidCycler™ and LightCycler™ from Idaho Technologies Inc. Other rapid PCR devices are described for example in co-pending British Patent Application Nos. 9625442.0 and  
10 9716052.7. The merits of rapid cycling over conventional thermal cycling have been reported elsewhere. Such techniques are particularly useful for example in detection systems for biological warfare where speed of result is important if loss of life or serious injury is to be  
15 avoided.

Furthermore, hydrolysis probes do not provide significant information with regard to hysteresis of melting since signal generation is, by and large, dependent upon  
20 hydrolysis of the probe rather than the melt temperature of the amplicon.

US Patent No. 5,491,063 describes a method for in-solution quenching of fluorescently labelled probes which relies on  
25 modification of the signal from a labelled single stranded oligonucleotide by a DNA binding agent. The difference in this signal which occurs as a result of a reduced chain length of the probe following probe cleavage (hydrolysis) during a polymerase chain reaction is suggested for  
30 providing a means for detecting the presence of a target nucleic acid.

Hybridisation probes are available in a number of forms. Molecular beacons are oligonucleotides that have  
35 complementary 5' and 3' sequences such that they form hairpin loops. Terminal fluorescent labels are in close proximity for FRET to occur when the hairpin structure is formed. Following hybridisation of molecular beacons to a

complementary sequence the fluorescent labels are separated, so FRET does not occur, and this forms the basis of detection.

5 Pairs of labelled oligonucleotides may also be used. These hybridise in close proximity on a PCR product strand bringing donor and acceptor molecules together so that FRET can occur. Enhanced FRET is the basis of detection. Variants of this type include using a labelled amplification  
10 primer with a single adjacent probe.

The use of two probes, or a molecular beacon type of probe which includes two labelling molecules increases the cost involved in the process. In addition, this method requires  
15 the presence of a reasonably long known sequence so that two probes which are long enough to bind specifically in close proximity to each other are known. This can be a problem in some diagnostic applications, where the length of conserved sequences in an organism which can be used to design an  
20 effective probe, such as the HIV virus, may be relatively short.

Furthermore, the use of pairs of probes involves more complex experimental design. For example, a signal provided  
25 when by the melt of a probe is a function of the melting off of both probes. The study of small mismatches or where one of the probes is required to bind across a splice region (for example to detect RNA as compared to DNA in a sample where the sequence on either side of an intron can be  
30 utilised as the probe site) can yield incorrect results if the other probe melts first.

US Patent No. 4,868,103 describes in general terms, a FRET system for detecting the presence of an analyte, which  
35 utilises an intercalating dye as the donor molecule. The process does not involve an amplification stage.

The applicants have developed a strand specific system for detecting the presence of particular nucleic acid sequences.

The invention provides a method for detecting the presence  
5 of a target nucleic acid sequence in a sample, said method comprising :

- (a) adding to a sample suspected of containing said target nucleic acid sequence, a DNA duplex binding agent, and a probe specific for said target sequence, said probe  
10 comprising a reactive molecule able to absorb fluorescence from or donate fluorescent energy to said DNA duplex binding agent,
- (b) subjecting the thus formed mixture to an amplification reaction in which target nucleic acid is amplified,
- 15 (c) subjecting said sample to conditions under which the said probe hybridises to the target sequence, and
- (d) monitoring fluorescence from said sample.

As used herein, the expression "DNA duplex binding agent"  
20 refers to any entity which adheres or associates itself with DNA in duplex form. These include intercalating dyes as are well known in the art.

As the probe hybridises to the target sequence in step (c),  
25 DNA duplex binding agent such as an intercalating dye is trapped between the strands. In general, this would increase the fluorescence at the wavelength associated with the dye. However, where the reactive molecule is able to absorb fluorescence from the dye (i.e. it is an acceptor  
30 molecule), it accepts emission energy from the dye by means of FET, especially FRET, and so it emits fluorescence at its characteristic wavelength. Increase in fluorescence from the acceptor molecule, which is of a different wavelength to that of the dye, will indicate binding of the probe in  
35 duplex form. Thus changes in fluorescence which are indicative of the formation or destabilisation of duplexes involving the probe are preferably monitored in step (d).



Similarly, where the reactive molecule is able to donate fluorescence to the dye (i.e. it is a donor molecule), the emission from the donor molecule is reduced as a result of FRET and this reduction may be detected. Fluoresence of the dye is increased more than would be expected under these circumstances.

Preferably the reactive molecule is an acceptor molecule as the signals are more readily determinable.

10

The use of a DNA duplex binding agent such as an intercalating dye and a probe which is singly labelled is advantageous in that these components are much more economical than other assays in which doubly labelled probes are required. By using only one probe, the length of known sequence necessary to form the basis of the probe can be relatively short and therefore the method can be used, even in difficult diagnostic situations.

Furthermore the method of the invention is extremely versatile in its applications. The method can be used to generate both quantitative and qualitative data regarding the target nucleic acid sequence in the sample, as discussed in more detail hereinafter. In particular, not only does the invention provide for quantitative amplification, but also it can be used, additionally or alternatively, to obtain characterising data such as duplex destabilisation temperatures or melting points.

In the method of the invention, the sample may be subjected to conditions under which the probe hybridises to the samples during or after the amplification reaction has been completed. The process therefore allows the detection to be effected in a homogenous manner, in that the amplification and monitoring can be carried out in a single container with all reagents added intially. No subsequent reagent addition steps are required. Neither is there any need to effect the

method in the presence of solid supports (although this is an option).

The probe may comprise a nucleic acid molecule such as DNA  
5 or RNA, which will hybridise to the target nucleic acid sequence when the latter is in single stranded form. In this instance, step (c) will involve the use of conditions which render the target nucleic acid single stranded.

10 Probe may either be free in solution or immobilised on a solid support, for example to the surface of a bead such as a magnetic bead, useful in separating products, or the surface of a detector device, such as the waveguide of a surface plasmon resonance detector. The selection will  
15 depend upon the nature of the particular assay being looked at and the particular detection means being employed.

In particular, the amplification reaction used will involve a step of subjecting the sample to conditions under which  
20 any of the target nucleic acid sequence present in the sample becomes single stranded. Such amplification reactions include the polymerase chain reaction (PCR) or the ligase chain reaction (LCR) but is preferably a PCR reaction.

25 It is possible then for the probe to hybridise during the course of the amplification reaction provided appropriate hybridisation conditions are encountered.

30 In a preferred embodiment, the probe may be designed such that these conditions are met during each cycle of the amplification reaction. Thus at some point during each cycle of the amplification reaction, the probe will hybridise to the target sequence, and generate a signal as a  
35 result of the FET or FRET between it and the DNA duplex binding agent such as the intercalating dye trapped between the probe and the target sequence. As the amplification proceeds, the probe will be separated or melted from the

target sequence and so the signal generated by it will reduce. Hence in each cycle of the amplification, a fluorescence peak from the reactive molecule is generated. The intensity of the peak will increase as the amplification proceeds because more target sequence becomes available for binding to the probe.

By monitoring the fluorescence of the reactive molecule from the sample during each cycle, the progress of the amplification reaction can be monitored in various ways. For example, the data provided by melting peaks can be analysed, for example by calculating the area under the melting peaks and this data plotted against the number of cycles.

For example, the fluorescence is suitably monitored using a known fluorimeter. The signals from these, for instance in the form of photo-multiplier voltages, are sent to a data processor board and converted into a spectrum associated with each sample tube. Multiple tubes, for example 96 tubes, can be assessed at the same time. Data may be collected in this way at frequent intervals, for example once every 10ms, throughout the reaction.

The spectra generated in this way can be resolved, for example, using "fits" of pre-selected dyes, to form peaks representative of each signalling moiety (i.e. dye and/or reactive molecule). The areas under the peaks can be determined which represents the intensity value for each signal, and if required, expressed as quotients of each other. The differential of signal intensities and/or ratios will allow changes in FRET to be recorded through the reaction or at different reaction conditions, such as temperatures. The changes, as outlined above, are related to the binding phenomenon between the probe and the target sequence. The integral of the area under the differential peaks will allow intensity values for the FRET effects to be calculated.

This data provides the opportunity to quantitate the amount of target nucleic acid present in the sample.

5 In addition, the kinetics of probe hybridisation will allow the determination, in absolute terms, of the target sequence concentration. Changes in fluorescence from the sample can allow the rate of hybridisation of the probe to the sample to be calculated. An increase in the rate of hybridisation  
10 will relate to the amount of target sequence present in the sample. As the concentration of the target sequence increases as the amplification reaction proceeds, hybridisation of the probe will occur more rapidly. Thus this parameter also can be used as a basis for  
15 quantification. This mode of data processing useful in that it is not reliant on signal intensity to provide the information.

Preferably, the fluorescence of both the dye and the  
20 reactive molecule are monitored and the relationship between the emissions calculated. This provides a strand specific measure to complement the generic DNA information provided by measuring fluorescence from the dye. In this way, the contribution to the signal of non-specific  
25 amplification can be distinguished and thus the method provides an internal check.

Suitable reactive molecules are rhodamine dyes or other dyes such as Cy5 or fluorescein. These may be attached to the  
30 probe in a conventional manner. The position of the reactive molecule along the probe is immaterial although in general, they will be positioned at an end region of the probe.

35 Intercalating dyes are well known in the art. They include for example SYBRGreen such as SYBRGreen I, SYBRGold, ethidium bromide and YOPRO-1.

- In order for FET, such as FRET, to occur between the reactive molecule and the dye, the fluorescent emission of the donor (which may either be the incalating dye or the reactive molecule on the probe) must be of a shorter wavelength than the acceptor (i.e the other of the dye or the reactive molecule).

Suitable combinations are therefore set out in the following Table:

Dye	Acceptor/Donor	Reactive molecule	Acceptor/Donor
SYBRGold	donor	rhodamine	acceptor
SYBRGreen I	donor	rhodamine	acceptor
SYBRGold	donor	Cy5	acceptor
SYBRGreen I	donor	Cy5	acceptor
Ethidium bromide	acceptor	Fluorescein	donor

10

- Preferably, the molecules used as donor and/or acceptor produce sharp peaks, and there is little or no overlap in the wavelengths of the emission. Under these circumstances, it may not be necessary to resolve the strand specific peak from the DNA duplex binding agent signal. A simple measurement of the strand specific signal alone (i.e. that provided by the reactive molecule) will provide information regarding the extent of the FRET caused by the target reaction. The ethidium bromide/fluorescein combination may fulfill this requirement. In that case, the strand specific reaction will be quantifiable by the reduction in fluorescence at 520nm, suitably expressed as 1/Fluorescence.

- However, where there is a spectral overlap in the fluorescent signals from the donor and acceptor molecules, this can be accounted for in the results, for example by determining empirically the relationship between the spectra and using this relationship to normalise the signals from the two signals.

30

It is possible to design the probe such that it is hydrolysed by the DNA polymerase used in the amplification reaction thereby releasing the reactive molecule. This provides a cumulative signal, with the amount of free  
5 reactive molecule present in the system increasing with each cycle. A cumulative signal of this type may be particularly preferred where the amount of target sequence is to be quantified. However, it is not necessary in this assay for the probe to be consumed in this way as the signal  
10 does not depend solely upon the dissociation of the probe.

In order to achieve a fully reversible signal which is directly related to the amount of amplification product present at each stage of the reaction, and/or where speed of  
15 reaction is of the greatest importance, for example in rapid PCR, it is preferable that the probe is designed such that it is released intact from the target sequence. This may be, for example, during the extension phase of the amplification reaction. However, since the signal is not  
20 dependent upon probe hydrolysis, the probe may be designed to hybridise and melt from the target sequence at any stage during the amplification cycle, including the annealing or melt phase of the reaction. Such probes will ensure that interference with the amplification reaction is minimised.

25 Where probes which bind during the extension phase are used, their release intact from the target sequence can be achieved by using a 5'-3' exonuclease lacking enzyme such as Stoffle fragment of Taq or Pwo.

30 In order to ensure that the probe is not extended during the extension phase of this, or indeed, any of the amplification reactions, the 3' end of the probe can be blocked, suitably by phosphorylation.

35 The probe may then take part again in the reaction, and so represents an economical application of probe.

The data generated in this way can be interpreted in various ways. In its simplest form, an increase in fluorescence of the acceptor molecule in the course of or at the end of the amplification reaction is indicative of an increase in the amount of the target sequence present, suggestive of the fact that the amplification reaction has proceeded and therefore the target sequence was in fact present in the sample. However, as outlined above, quantitation is also possible by monitoring the amplification reaction throughout. In addition, the emissions from the DNA duplex binding agent, in particular the intercalating dye, can be used in order to monitor the bulk rise in nucleic acid in the sample and this can be compared to the strand specific amplification, as measured by the relationship between the reactive molecule and dye signals. Finally, it is possible to obtain characterisation data and in particular melting point analysis, either as an end point measure or throughout, in order to obtain information about the sequence as will be discussed further below.

20

Thus, a preferred embodiment of the invention comprises a method for detecting nucleic acid amplification comprising: performing nucleic acid amplification on a target polynucleotide in the presence of (a) a nucleic acid polymerase (b) at least one primer capable of hybridising to said target polynucleotide, (c) a fluorescent DNA duplex binding agent and (d) an oligonucleotide probe which is capable of binding to said target polynucleotide sequence and which contains an acceptor molecule which is capable of absorbing fluorescence from the said dye; and monitoring changes in fluorescence during the amplification reaction.

As before, the DNA duplex binding agent is suitably an intercalating dye. The amplification is suitably carried out using a pair of primers which are designed such that only the target nucleotide sequence within a DNA strand is amplified as is well understood in the art. The nucleic

35

acid polymerase is suitably a thermostable polymerase such as Taq polymerase.

Suitable conditions under which the amplification reaction  
5 can be carried out are well known in the art. The optimum conditions may be variable in each case depending upon the particular amplicon involved, the nature of the primers used and the enzymes employed. The optimum conditions may be determined in each case by the skilled person. Typical  
10 denaturation temperatures are of the order of 95°C, typical annealing temperatures are of the order of 55°C and extension temperatures are of the order of 72°C.

The method can be used in hybridisation assays for  
15 determining characteristics of particular sequences.

Thus in a further aspect, the invention provides a method for determining a characteristic of a sequence, said method comprising;

- 20 (a) adding to a sample suspected of containing said sequence, DNA duplex binding agent and a probe specific for said target sequence and, said probe comprising a reactive molecule able to absorb fluorescence from or donate fluorescent energy to said DNA duplex binding agent,  
25 (b) subjecting said sample to conditions under which the said probe hybridises to the target sequence,  
(c) monitoring fluorescence from said sample and determining a particular reaction condition, characteristic of said sequence, at which fluorescence changes as a result of the  
30 hybridisation of the probe to the sample or destabilisation of the duplex formed between the probe and the target nucleic acid sequence.

Suitable reaction conditions include temperature,  
35 electrochemical, or the response to the presence of particular enzymes or chemicals. By monitoring changes in fluorescence as these properties are varied, information characteristic of the precise nature of the sequence can be



achieved. For example, in the case of temperature, the temperature at which the probe separates or "melts" from the target sequence can be determined. This can be extremely useful in for example, to detect and if desired also to  
5 quantitate, polymorphisms in sequences including allelic variation in genetic diagnosis. By "polymorphism" is included transitions, transversions, insertions, deletions of inversions which may occur in sequences, particularly in nature.

10

The hysteresis of melting of the probe will be different if the target sequence varies by only one base pair. Thus where a sample contains only a single allelic variant, the temperature of melting of the probe will be a particular  
15 value which will be different from that found in a sample which contains only another allelic variant. A sample containing both allelic variants which show two melting points corresponding to each of the allelic variants.

20 Similar considerations apply with respect to electrochemical properties, or in the presence of certain enzymes or chemicals. The probe may be immobilised on a solid surface across which an electrochemical potential may be applied. Target sequence will bind to or be repulsed from the probe  
25 at particular electrochemical values depending upon the precise nature of the sequence.

This embodiment can be effected in conjunction with amplification reactions such as the PCR reaction mentioned  
30 above, or it may be employed individually. Again, the reactive molecule is preferably an acceptor molecule.

Further aspects of the invention include kits for use in the method of the invention. These kits will contain a probe  
35 specific for a target nucleotide sequence which contains a reactive molecule. Additionally, they may contain a DNA duplex binding agent such as an intercalating dye which is compatible in terms of being able to undergo FET or FRET

with said reactive molecule. Other potential components of the kit include reagents used in amplification reactions such as DNA polymerase.

- 5 The invention will now be particularly described by way of example with reference to the accompanying diagrammatic drawings in which:

Figure 1 shows diagrammatically the interactions which are  
10 utilised in the process of the invention;

Figure 2 illustrates stages during an amplification reaction in accordance with the invention;

- 15 Figure 3 shows the results of an amplification reaction in accordance with the invention, and

Figure 4 shows the results of a experiment to detect mismatches in sequences.

20

Figure 1A illustrates the action of an intercalating dye (1) which is in the presence of single stranded DNA (2), as would be found during the melt phase of a PCR reaction. The dye attaches to the DNA strands and fluoresce at a  
25 certain level. However, when the DNA becomes double stranded (3), the dye is concentrated and the fluorescence increases significantly. This increase in fluorescence can be used to detect the formation of double stranded DNA. The fluorescence of the dye will be at a particular wavelength,  
30 for example in the green region of the spectrum.

The effect of intercalating dye (1) on a probe (4) in accordance with the invention is illustrated in Figure 1C. Some dye will bind to the nucleotides of the probe and will  
35 fluoresce at the background level. However, as a result of FRET, some energy will pass to the acceptor molecule (5) as indicated by the arrow and so this molecule will also

fluoresce but at a different wavelength to that of the dye, for example, in the red region of the spectrum.

When the probe hybridises with a single stranded target  
5 sequence as illustrated in Figure 1D, any increase in the  
fluorescent energy from the dye passes to the acceptor  
molecule (5) which thus fluoresces at a higher level.  
Increase in the fluorescence of the acceptor molecule will  
thus be indicative of hybridisation of the probe to the  
10 target sequence. Thus by measuring the increase in  
fluorescence of the acceptor molecule, for example as the  
temperature decreases, the point at which hybridisation  
occurs can be detected. Similarly, a decrease in acceptor  
fluorescence will occur as the temperature increases at the  
15 temperature at which the probe melts from the target  
sequence. This will vary depending upon the hybridisation  
characteristics of the probe and the target sequence. For  
example, a probe which is completely complementary to a  
target sequence will melt at a different temperature to a  
20 probe which hybridises with the target sequence but contains  
one or more mismatches.

Figure 2 illustrates how the method of the invention can be  
employed in amplification reactions such as the PCR  
25 reaction. Probe (4) will hybridise to single stranded DNA  
in conjunction with the intercalating dye (1) and thus  
generate an increased acceptor signal (Figure 2A). This  
will occur during the annealing phase of the cycle. As the  
amount of target sequence increases as a result of the  
30 amplification, the signal generated during the annealing  
phase by the acceptor molecule will also increase.

During the extension phase, the probe is removed from the  
target sequence either by hydrolysis or, as illustrated,  
35 because it is displaced by the DNA polymerase. At this  
point, the acceptor signal decreases although the signal  
from the dye (1) will be enhanced, again indicative of the  
increase in the amount of target sequence.

By monitoring the progress of the amplification reaction in this manner, the quantity of target sequence present in the original sample can be quantitated.

5

#### Example 1

##### PCR amplification reaction

PCR reaction mixtures contained the following reagents, working concentrations were prepared:

- 10 1x native PCR Buffer (3mM Mg++, Bio/Gene, Bio/Gene House, 6 The Business Centre, Harvard Way, Kimbolton, Cambridge, PE18 ONJ, UK). Taq DNA polymerase 0.025 units/ $\mu$ l, and dNTP's PCR nucleotides 200 $\mu$ M (Boehringer Mannheim UK (Diagnostics & Biochemical) Limited, Bell Lane, Lewes, East Sussex, BN7
- 15 1LG, UK). Custom oligonucleotide primers 1 $\mu$ M each (Cruachem Ltd, Todd Campus, West of Scotland Science Park, Acre Road, Glasgow G20 0UA, UK). Plasmid DNA was added to a final concentration of 10fg/ $\mu$ l (~3000 copies). In a negative control experiment, a similar PCR was carried out in the
- 20 absence of plasmid DNA.

- The forward YPPA155 (dATGACGCAGAAACAGGAAGAAAGATCAGCC) and reverse YPP229R (dGGTCAGAAATGAGTATGGATCCCAGGATAT) primers select a 104 bp amplicon of the anti-coagulase gene of
- 25 *Yersinia pestis*. This has previously been cloned into to pBluescript SK vector (Stratagene Europe, Hogehilweg 15, 1101 CB Amsterdam, Zuidoost, The Netherlands) to form the phagemid construct pYP100ML.

- 30 The fluorescent probe (5' (CY5)CGCTATCCTGAAAGGTGATATATCCTGG, Bio/Gene, Bio/Gene House, 6 The Business Centre, Harvard Way, Kimbolton, Cambridge, PE18 ONJ, UK) was added to a final concentration of 0.2 $\mu$ M. SyberGold DYE (Molecular Probes) was added to a final concentration of 1:400,000 of
- 35 the reference concentration.

The reaction was thermal cycled in composite glass capillaries and an Idaho Technology Lightcycler (Bio/Gene, Bio Gene House, 6 The Business Centre, Harvard Way, Kimbolton, Cambridge, PE18 0NJ, UK). The cycle was 95°C for 1 Sec, 55°C for 1 Sec, and 74°C for 1 Sec.

Following the thermal cycle a melting experiment was carried out from 55°C to 95°C at 0.1 °C/Sec. The reaction was optically interrogated using the LightCycler™, the fluorescent emission at 520 & 670nm were recorded.

The results, expressed as a function of the differential of fluorescence (F) against temperature (T)  $dF/dT$  plotted against temperature on the Y axis, is shown in Figure 3. At 520nm, only the fluorescence from the SybrGold is recorded. A clear peak associated with the melt temperature of the specific product, which has been amplified in the PCR reaction. The negative control shows only artefacts.

At 670nm, both signal from the CY5 acceptor molecule and also signal from the SybrGold is recorded. The peak indicative of the specific amplification product is observed in the positive experiment but is lacking in the negative control where again only artefacts are shown. However, additionally in this case, a clear peak resulting from melting of the probe is observed in the positive experiment.

#### Example 2

The following materials were used.

Oligonucleotides:

Probe: 5' (CY5)CGCTATCCTGAAAGGTGATATATCCTGGGA 3'

Homologue : 5' TCCCAGGATATATCACCTTTCAGGATAGCG 3'

Mismatch 1 : 5' TCCCAGGATATATCAGCTTTCAGGATAGCG 3'

Mismatch 2 : 5' TCCCAGGATATATCAGGTTTCAGGATAGCG 3'

Mismatch 3 : 5' TCCCAGGATATATCTTTCAGGATAGCG 3'

(Bio/Gene Limited, Bio/Gene House, 6 The Business Centre, Harvard Way, Kimbolton, Cambridgeshire, PE18 0NJ)

Intercalator:

SYBR Green I (Molecular Probes)

Hybridisation buffer:

- 5 PCRM0012 (Bio/Gene Limited, Bio/Gene House, 6 The Business  
Centre, Harvard Way, Kimbolton, Cambridgeshire, PE18 0NJ)

Fluorimeter:

- Idaho Technology LC32 (Bio/Gene Limited, Bio/Gene House, 6 The  
10 Business Centre, Harvard Way, Kimbolton, Cambridgeshire, PE18  
0NJ)

Methods:

- 4µl hybridisation mixtures were assembled to consist of the  
15 following:

PCRM012: Working concentration as defined by manufacturer  
SYBR Green I: 1/20,000 concentration of reference solution  
Probe oligonucleotide: 100µM

- 20 Target oligonucleotide: 100µM

- Hybridisation mixtures were subjected to the following  
temperature regime in the LightCycler. Heating to 95°C at  
20°C/s, cooling to 50°C at 20°C/s, holding at 50°C for 10s,  
25 heating to 80°C at 0.1°C/s. Fluorescence was monitored in two  
channels during the final heating step, F1 (520nm-580nm) with  
gain set to 16 and F2 (650nm-690nm) with gain set to 128.

- Spectral overlap from SYBR Green I into F2 was removed from F2  
30 fluorescence using the following empirically determined  
relationship:  $F2 \text{ overlap} = 0.3232 \times F1 + 4.2853$ . The SYBR  
Green I independent component of F2 was normalised and plotted  
on the Y axis against temperature on the X axis, as shown in  
Figure 4. The results show the dependence of probe  
35 dissociation temperature on the nature of the sequence  
targeted. Single base differences in the targeted sequence are  
clearly discriminable.

## Claims

1. A method for detecting the presence of a target nucleic acid sequence in a sample, said method comprising:
- 5 (a) adding to a sample suspected of containing said target nucleic acid sequence, a DNA duplex binding agent, and a probe specific for said target sequence, said probe comprising a reactive molecule able to absorb fluorescence from or donate fluorescent energy to said DNA duplex binding agent,
- 10 (b) subjecting the thus formed mixture to an amplification reaction in which target nucleic acid is amplified,
- (c) subjecting said sample to conditions under which the said probe hybridises to the target sequence, and
- 15 (d) monitoring fluorescence from said sample.
2. A method according to claim 1 wherein fluorescence associated with the formation and destabilisation of duplexes involving the probe is determined.
- 20 3. A method according to claim 1 or claim 2 wherein the reactive molecule is an acceptor molecule able to absorb fluorescence from said DNA duplex binding agent.
- 25 4. A method according to any one of the preceding claims wherein the DNA duplex binding agent is an intercalating dye.
5. A method according to any one of the preceding claims wherein the target nucleic acid is rendered single stranded prior to hybridisation to the probe in step (c).
- 30 6. A method according to any one of the preceding claims wherein the amplification reaction is the polymerase chain reaction (PCR).
- 35

7. A method according to any one of the preceding claims wherein the probe hybridises with the target nucleic acid during every cycle of the amplification reaction.

5 8. A method according to claim 7 wherein the probe hybridises with the target nucleic acid during a phase other than the extension phase of the amplication cycle.

9. A method according to claim 7 or claim 8 wherein the  
10 fluorescence from the sample is monitored throughout the amplification reaction.

10. A method according to claim 9 wherein fluorescence data generated is used to determine the relative amounts of  
15 fluorescence from the donor and acceptor molecules through the reaction, or the rates of probe hybridisation.

11. A method according to any one of claims 7 to 10 wherein the fluorecence data is used to quantitate the  
20 amount of target nucleic acid present in the sample.

12. A method according to any one of the preceding claims wherein the fluorecence from both the dye and the reactive molecule are monitored.

25 13. A method according to any one of the preceding claims wherein the reactive molecule is a rhodamine dye, Cy5 or fluorescein.

30 14. A method according to any one of the preceding claims wherein the reactive molecule is attached at an end region of the probe.

15. A method according to anyone of the preceding claims  
35 wherein the probe is designed such that it is hydrolysed by the DNA polymerase used in the amplification reaction.



16. A method according to any one of claims 1 to 14 wherein the probe is released intact from the target sequence.
- 5 17. A method according to claim 16 wherein the amplification reaction is effected using 5'-3' exonuclease lacking enzyme.
- 10 18. A method according to any one of the preceding claims wherein the 3' end of the probe is blocked to inhibit extension thereof during the extension phase.
- 15 19. A method according to claim 1 which comprises performing nucleic acid amplification on a target polynucleotide in the presence of (a) a nucleic acid polymerase (b) at least one primer capable of hybridising to said target polynucleotide, (c) a fluorescent DNA duplex binding agent and (d) an oligonucleotide probe which is capable of binding to said target polynucleotide sequence and which contains an acceptor molecule which is capable of absorbing fluorescence from the said DNA duplex binding agent; and monitoring changes in fluorescence during the amplification reaction.
- 20 20. A method according to claim 19 wherein the amplification is suitably carried out using a pair of amplification primers.
- 25 21. A method according to claim 19 or claim 20 wherein the nucleic acid polymerase is suitably a thermostable polymerase.
- 30 22. A method according to anyone of the preceding claims wherein in a further step, a hybridisation assay is carried out and a hybridisation condition which is characteristic of the sequence is measured.
- 35

23. A method according to claim 22 wherein the condition is temperature, electrochemical potential, or reaction with an enzyme or chemical.

5 24. A method according to claim 23 wherein the condition is temperature.

25. A method according to claim 24 which is used to detect allelic variation or a polymorphism in a target sequence.

10

26. A method for determining a characteristic of a sequence, said method comprising;

(a) adding to a sample suspected of containing said sequence, a probe specific for said target sequence DNA duplex binding agent, said probe comprising a reactive molecule able to absorb fluorescence from or donate fluorescent energy to said DNA duplex binding agent,

(b) subjecting said sample to conditions under which the said probe hybridises to the target sequence,

20 (c) monitoring fluorescence from said sample and determining a particular reaction condition, characteristic of said sequence, at which fluorescence changes as a result of the hybridisation of the probe to the sample or destabilisation of the duplex formed between the probe and the target nucleic acid sequence.

27. A method according to claim 26 wherein the reaction condition characteristic of said sequence is temperature, electrochemical potential, or reaction with an enzyme or chemical.

28. A method according to claim 27 wherein the condition is temperature.

35 29. A method according to any one of claims 26 to 28 wherein the results obtained from two sequences are compared in order to determine the presence of polymorphisms or variations therebetween.

30. A method according to any one of claims 26 to 29 wherein the DNA duplex binding agent is an intercalating dye.

5

31. A kit for use in the method according to any one of the preceding claims, which kit comprises a probe specific for a target nucleotide sequence which contains an reactive molecule, and a DNA duplex binding agent which is compatible  
10 with said reactive molecule.

32. A kit according to claim 31 wherein the DNA duplex binding agent is an intercalating dye.

15 33. A kit according to claim 31 or 32 which further comprises one or more reagents used in an amplification reaction.

20 34. A probe for use in a method according to any one of the preceding claims which comprises a sequence which will hybridise with a target nucleotide sequence and a reactive molecule.

Figure 1




Figure 2






Figure 3

SIGNAL AT 520 NM




SIGNAL AT 670 NM



4/4

Figure 4



# INTERNATIONAL SEARCH REPORT

Intern. Appl. No.

PCT/GB 98/03560

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 491 063 A (FISHER M. E. AND WATSON R. M.) 13 February 1996 cited in the application see column 3, line 22 - line 30 see column 8, line 23 - column 9, line 32; claims	1-15, 19-21, 31-34
X	WO 95 08642 A (ZENECA LTD) 30 March 1995  see page 14, line 21 - page 16, line 16; claims	1-14, 18-21, 31-34

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

23 April 1999

Date of mailing of the international search report

04/05/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Luzzatto, E



# INTERNATIONAL SEARCH REPORT

Intern. Application No

PCT/GB 98/03560

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 868 103 A (STAVRIANOPOULOS J. ET AL.) 19 September 1989 cited in the application	31,32,34
Y	see column 6, line 22 - line 28 see column 11, line 54 - column 12, line 34 see column 14, line 5 - column 17, line 58 see column 27, line 10 - column 28, line 60; claims	1,26
Y	EP 0 512 334 A (F. HOFFMANN-LA ROCHE) 11 November 1992 see the whole document	1
Y	WO 97 12030 A (NANOGEN) 3 April 1997 see page 14, line 23 - page 15, line 2; figures 12,13 see page 38, line 25 - page 43, line 26; claims	26

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern. Patent Application No

PCT/GB 98/03560

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5491063 A	13-02-1996	EP 0699768 A JP 8070876 A	06-03-1996 19-03-1996
WO 9508642 A	30-03-1995	AU 7662794 A EP 0720659 A GB 2283095 A,B JP 9503660 T US 5827653 A	10-04-1995 10-07-1996 26-04-1995 15-04-1997 27-10-1998
US 4868103 A	19-09-1989	CA 1285330 A DE 3778958 A EP 0242527 A JP 2823119 B JP 62240864 A	25-06-1991 17-06-1992 28-10-1987 11-11-1998 21-10-1987
EP 512334 A	11-11-1992	AU 665185 B AU 1513892 A CA 2067909 A CA 2218818 A EP 0872562 A JP 10201464 A JP 5184397 A NZ 242565 A	21-12-1995 05-11-1992 03-11-1992 03-11-1992 21-10-1998 04-08-1998 27-07-1993 26-07-1994
WO 9712030 A	03-04-1997	US 5849486 A AU 6968996 A CA 2233238 A CN 1202929 A EP 0852617 A	15-12-1998 17-04-1997 03-04-1997 23-12-1998 15-07-1998